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cant. HighBAI/highBDI was signiﬁcantly different than the other
groups (p < 0.01). This pattern was similar for social function,
role emotion, mental health. Physical-related SF-36 domains
were generally not different between groups. The difference in
work-performance scale scores followed the same general pattern
of less impairment with lowBAI/lowBDI (for example, WPAI-
Percent Impairment While Working scale 0.22 + 0.3) and
highBAI/highBDI (WPAI Percent Impairment While Working
0.77 + 0.2), p < 0.01. Other work scales followed a similar
pattern. BDI routinely was more signiﬁcant in regression models
compared to BAI. CONCLUSION: Comorbid anxiety and
depression greatly impair patients. Clinicians and researchers
should measure the presence and severity of both mental illnesses
when assessing their inﬂuence on health-related quality of life
and work-performance.
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OBJECTIVE: While the clinical efﬁcacy of drugs for ADHD is
widely studied in clinical trials (usually randomised controlled
trials, RCTs), patient preferences with regard to their treatments
are not well understood and therefore considered to a less extent.
Aim of this study therefore was to explore the patients’ percep-
tions of an “ideal treatment” for ADHD. METHODS: Exami-
nation of the state of the art as reported in the literature was
followed by a qualitative study with four focus groups consisting
of 6–8 parents of ADHD-patients each. In a subsequent quanti-
tative study phase, data was collected in an online or paper-pencil
self-ﬁll-in questionnaire for parents of patients and patient (age
>14 years) themselves. It included sociodemographic data, treat-
ment history and actual treatment and patients’ preferences of
therapy characteristics using direct measurement (23 items on
a 5-point Likert-scale) as well as a discrete-choice-experiment
(DCE, 8 pairs with 6 characteristics). RESULTS: N = 213 ques-
tionnaires were ﬁlled; most of them by the parents of patients
(79% by the mothers, 9% by the fathers). Most of the patients
were male (83%) and most of them (83%) had actual medical
treatment of ADHD. Direct measurement showed “good emo-
tional quality of live”, “no addiction on medication”, “improve-
ment of concentration capability,” and “few side effects” in the
ﬁrst places. In the DCE, alternatives with “better social quality of
life (friendships etc. possible)”, “better emotional quality of life
(disease not all of the time mentally present)”, and “longer
duration of medication effect” were more likely to be chosen,
giving thus similar results. CONCLUSION: This unique study
demonstrates that it is possible to obtain valid and robust infor-
mation from patients on what constitutes relevant patient out-
comes. Such information should play a critical role in appraisal
of treatment alternatives by HTA bodies.
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OBJECTIVE: The functional rating scale (FRS) and clinical
dementia rating (CDR) scale are two different tests used to assess
the severity and progression of dementia. Although the FRS
covers more domains and requires less time to administer than
the CDR, the CDR categorizes severity of dementia while the
FRS does not. The purpose of this research was to calculate the
agreement between the FRS and CDR scales and to determine if
they could be used interchangeably for diagnosis of disease sever-
ity in vascular dementia (VaD). METHODS: Inpatients and out-
patients diagnosed with VaD/mixed VaD were evaluated using
the FRS and CDR scales. The tests were administered indepen-
dently by two separate raters. Since the FRS contains all of the
domains that are rated in the CDR, CDR scores were extracted
from the corresponding FRS domains and used to derive global
scores of severity. FRS-derived global scores were then compared
to original CDR global scores by a weighted kappa analysis to
measure concordance. RESULTS: A total of 28 VaD/mixed VaD
patients were involved in the study. In the patient population,
60.7% were males and average age was 78.6  7.7 years.
Average MMSE score was 19.9  4.8 while mean Hachinski
score was 8.1  2.8. The modal value obtained for both the
FRS-derived CDR scores and original CDR scores was 2; in both
groups scores ranged from 0.5–3 with 43% of patients diagnosed
in category 2 (moderate dementia). The weighted kappa analysis
showed substantial concordance (kappa = 0.75) between FRS-
derived CDR and original CDR-global scores. CONCLUSION:
These results suggest that FRS scores can be used to derive global
scores that are in agreement with those produced by the validated
CDR method. This serves as a powerful tool since it allows for
easy comparison of the diagnostic distribution, natural history
and treatment outcomes of individuals with dementia.
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OBJECTIVE: Signal detection and, ultimately, regulatory
approval depend on high-quality, valid and reliable data. The
subjective rating scales utilized in CNS clinical trials may be
vulnerable to spurious ratings and intentional or unintentional
manipulation of ratings by investigators at screening or baseline
visits. The objective of this study was to evaluate the feasibility of
utilizing a patient reported outcome as a quality assurance
measure for evaluation of the quality of a clinician rated primary
efﬁcacy measure in a CNS clinical trial. METHODS: A propri-
etary ratings surveillance system was utilized in a multi-center,
double blind, randomized, placebo-controlled clinical trial in
which the Hamilton Anxiety Rating Scale (HARS) was the
primary efﬁcacy measure. The patient rated Beck Anxiety Inven-
tory (BAI) was added to the baseline visit for quality assurance
purposes. Based on published guidelines of the expected relation-
ship between HARS and BAI scores, a computer program ﬂagged
aberrant ratings and three ﬂags with the same rater triggered
a teaching intervention. The ratings surveillance system was
intended both to detect aberrant rating patterns and to deter
intentional inﬂation of ratings in order to qualify subjects.
RESULTS:The clinical trial is ongoing. 91 pairs of HARS and BAI
ratings have been examined from the randomization visit. 61/91
(67%) pairswere ﬂagged for discordance, inmost cases (79%) due
to disproportionately high HARS scores compared to the BAI. In
8 cases, the BAI was under 10 with the HARS 22 or greater. In 11
cases, there were at least 3 ﬂags for the same rater and the pattern
of discordance was considered to be of sufﬁcient clinical signiﬁ-
cance to warrant a teaching intervention. CONCLUSION: Use of
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patient reported outcomes as a measure of quality of clinician
reported outcomes appears to be a feasible tactic in a site-based
ratings surveillance quality assurance system.
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OBJECTIVE: Major depressive disorder (MDD) is a leading
cause of disability worldwide. This study analyzed the literature
describing the burden of MDD in North America (USA and
Canada), with particular focus on patients with treatment-
resistant depression (TRD). METHODS: Systematic searches
were conducted of English-language papers published between
1987 and 2007, utilizing MEDLINE, EMBASE, and the
Cochrane Library, relevant websites, and hand searches. Major
areas for review were the humanistic and economic burden of
MDD. Additional areas for analysis included treatment options
and costs, treatment efﬁcacy and response rates, treatment guide-
lines, and reimbursements. RESULTS: A total of 908 articles
were identiﬁed, of which 107 studies from North America ful-
ﬁlled the inclusion criteria (humanistic burden, N = 45; economic
burden, N = 49; and treatment guidelines, N = 13). Analysis of
these studies identiﬁed an increased humanistic and economic
burden in patients with MDD and TRD in North America. MDD
was associated with a high prevalence (3–31%), was chronic in
nature, and had a high frequency of comorbid mental disorders.
Health-related quality of life (HRQL) instruments identiﬁed a
signiﬁcant negative impact from MDD, including domains of
mental well-being (independence, alertness, role emotional,
personal/spiritual beliefs) and perceived physical functioning
(energy and fatigue, bodily care). In a study that compared
HRQL in responders and non-responders to therapy, HRQL was
signiﬁcantly lower in non-responders (P < 0.001). Patients with
TRD were particularly severely affected, through higher medical
costs and greater losses in work productivity. CONCLUSION:
Patients with MDD and their families suffer greater humanistic
and economic burden than healthy individuals. Treatment
reduces the burden of MDD, although current evidence-based
guidelines for MDD offer limited recommendations on the choice
of pharmacological treatments based on their potential to reduce
burden of illness and resource use.
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OBJECTIVE: Though antipsychotics were originally developed
to treat schizophrenia, their use in older adults with dementia has
grown substantially. Given concern about the safety of these
drugs, we assessed the impact of a prior authorization (PA) policy
upon use and choice of antipsychotic medication in long-term
care. METHODS: We conducted a retrospective cohort study
using administrative data from two Canadian provinces—one in
which access to newer antipsychotics (risperidone, olanzapine,
and quetiapine) was unrestricted (Ontario), and another in which
access required PA (British Columbia (BC)). Subjects were all
37,057 Ontario and 13,569 BC residents aged 66 years or older
who were newly admitted to a nursing home between April 1,
1998 and March 31, 2002, who had no history of schizophrenia
or psychosis in the 5 years preceding admission, and who had no
evidence of antipsychotic drug use in the preceding year. We
assessed crude and adjusted exposure to antipsychotic medica-
tion over the year following nursing home admission, as well as
the types of medications used. RESULTS: Nineteen percent of
Ontario residents were newly dispensed an antipsychotic within
100 days of nursing home admission vs. 16% in BC. Male sex,
younger age, fewer comorbidities, and history of dementia all
were strongly associated with receipt of an antipsychotic. Adjust-
ment for these factors reduced the cross-provincial difference in
drug use. However, fewer BC residents received newer anti-
psychotics, particularly after risperidone received an approved
indication for the management of behavioural symptoms of
dementia. Olanzapine, which required PA throughout the study,
was dispensed to 11% and 3% of Ontario and BC residents,
respectively. CONCLUSION: Although BC’s PA policy had neg-
ligible impact upon the incidence of antipsychotic drug use as a
whole, it appeared to inﬂuence drug choice. Questions remain
about the impact of such policies upon health outcomes and
costs.
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OBJECTIVE: The 2002 Veterans Health Care Act raised medi-
cation copayments from $2 to $7 for lower priority patients.
Veterans with schizophrenia constitute a multiply disadvantaged
population; 40% are antipsychotic non-adherent, substantially
increasing psychiatric admission risks. Certain patient sub-
groups might be particularly sensitive to medication costs with
signiﬁcant clinical ramiﬁcations. Diverse cultural expressions of
health beliefs and priorities contribute additional layers of com-
plexity. This study examines potential inequities stemming from
higher copayments. METHODS: All veterans with schizophrenia
were followed 33 months Pre and Post copayment increase.
Longitudinal models analyzed effects of higher medication costs
in copayment veterans versus a natural control group of exempt
patients, controlling for demographics, substance abuse, func-
tional status, and other comorbidities. Adjusted means compared
prescription patterns and inpatient utilization among four ethnic
groups: white (N = 36,452), African-American (N = 17,602),
Hispanic (N = 5,225), and Other (N = 10,707). RESULTS:
African-Americans were relatively younger with higher substance
abuse rates. Hispanic veterans were more likely to be unmarried
and have multiple illnesses, though fewer (39%) faced copay-
ments than other patients. Minorities ﬁlled 10–35% fewer pre-
scriptions than white veterans, and ethnic differences were
evident in pharmacy ﬁlls and inpatient days. White veterans
reduced psychotropic ﬁlls 15% after the policy change, decreas-
ing hospital days by nearly the same amount. However, mi-
norities dropped psychotropics 19%–22% while subsequently
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